Short-term efficacy of endovascular procedures for lower extremity thromboangiitis obliterans (Buerger’s disease)

References

• Li MD, Wang YF, Yang MW, et al. Risk factors, mechanisms and treatments of thromboangiitis obliterans: an overview of recent research. Curr Med Chem. 2020;27(35):6057–6072. doi: 10.2174/0929867326666190816233042
   PubMed Web of Science ®Google Scholar
• Olin JW. Thromboangiitis obliterans: 110 years old and little progress made. J Am Heart Assoc. 2018;7(23):e011214. doi: 10.1161/JAHA.118.011214
   PubMed Web of Science ®Google Scholar
• Ye K, Shi H, Qin J, et al. Outcomes of endovascular recanalization versus autogenous venous bypass for thromboangiitis obliterans patients with critical limb ischemia due to tibioperoneal arterial occlusion. J Vasc Surg. 2017;66(4):1133–1142 e1. doi: 10.1016/j.jvs.2017.03.425
   PubMed Web of Science ®Google Scholar
• Yan K, Yuan ZH, Zheng Y, et al. Clinical outcomes in patients with infrapopliteal arterial occlusive disease treated by lower extremity bypass surgery: a comparison of atherosclerosis and thromboangiitis obliterans. Eur Rev Med Pharmacol Sci. 2022;26(12):4228–4237. doi: 10.26355/eurrev_202206_29059
   PubMed Web of Science ®Google Scholar
• Hatta H, Setiawan E, Triani ZD, et al. Successful lumbal sympathetic block as an alternative therapy for improving Buerger’s disease: a rare case report and literature review. Int J Surg Case Rep. 2023;110:108778. doi: 10.1016/j.ijscr.2023.108778
   PubMed Web of Science ®Google Scholar
• Davies MG, Saad WE, Peden EK, et al. Impact of runoff on superficial femoral artery endoluminal interventions for rest pain and tissue loss. J Vasc Surg. 2008;48(3):619–625; discussion 625–6. doi: 10.1016/j.jvs.2008.04.013
   PubMed Web of Science ®Google Scholar
• Carneiro FCF, Almeida BM, Cacione DG. Endovascular treatment for thromboangiitis obliterans (Buerger’s disease). Cochrane Database Syst Rev. 2023;2023(1). doi: 10.1002/14651858.CD014886
   Google Scholar
• Kim DH, Ko YG, Ahn CM, et al. Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease. J Vasc Surg. 2018;67(6):1769–1777. doi: 10.1016/j.jvs.2017.09.020
   PubMed Web of Science ®Google Scholar
• Kawarada O, Kume T, Ayabe S, et al. Endovascular therapy outcomes and intravascular ultrasound findings in thromboangiitis obliterans (Buerger’s disease). J Endovasc Ther. 2017;24(4):504–515. doi: 10.1177/1526602817710917
   PubMed Web of Science ®Google Scholar
• Zeng R, Ye W, Li YJ, et al. Revascularization for lower limbs thromboangiitis obliterans-early and mid-term outcome report. Zhonghua Wai Ke Za Zhi. 2013;51(8):719–722.
   PubMedGoogle Scholar
• Wu S, Sun X, Wu W, et al. Effect of revascularization on IL-6 and TNF-alpha in patients with thromboangiitis obliterans. Exp Ther Med. 2018;15(4):3947–3951. doi: 10.3892/etm.2018.5877
   PubMed Web of Science ®Google Scholar
• Ghoneim BM, Karmota AG, Abuhadema AM, et al. Management of Buerger’s disease in endovascular era. Int J Angiol. 2019;28(3):173–181. doi: 10.1055/s-0039-1685200
   PubMed Web of Science ®Google Scholar
• Yuan L, Bao J, Zhao Z, et al. Clinical results of percutaneous transluminal angioplasty for thromboangiitis obliterans in arteries above the knee. Atherosclerosis. 2014;235(1):110–115. doi: 10.1016/j.atherosclerosis.2014.04.006
   PubMed Web of Science ®Google Scholar
• Rodoplu O, Yildiz CE, Oztas DM, et al. The efficacy of percutaneous transluminal angioplasty on the limb salvage and recovery of symptoms in patients with Buerger’s disease with critical limb ischemia. J Invasive Cardiol. 2020;32(6):E158–E167.
   PubMed Web of Science ®Google Scholar
• Modaghegh MS, Hafezi S. Endovascular treatment of thromboangiitis obliterans (Buerger’s Disease). Vasc Endovascular Surg. 2017;52(2):124–130. doi: 10.1177/1538574417744085
   PubMed Web of Science ®Google Scholar
• Li FQ, Li L, He XW, et al. Percutaneous transluminal angioplasty combined with intra-arterial thrombolysis to treat lower-extremity arterial occlusion in thromboangitis. Int Angiol. 2016;35(5):440–445.
   PubMed Web of Science ®Google Scholar
• Wang CC, Lu CR, Hsieh LC, et al. Comparison of pharmaco-mechanical thrombolysis and catheter-directed thrombolysis for treating thrombotic or embolic arterial occlusion of the lower limb. Int Angiol. 2022;41(4):292–302. doi: 10.23736/S0392-9590.22.04809-X
   PubMed Web of Science ®Google Scholar
• Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–538. doi: 10.1016/S0741-5214(97)70045-4
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Miyata T, Shigematsu K, et al. Current trends in epidemiology and clinical features of thromboangiitis obliterans in Japan　- a nationwide survey using the medical support system database. Circ J. 2020;84(10):1786–1796. doi: 10.1253/circj.CJ-19-1165
   PubMed Web of Science ®Google Scholar
• Conte MS. Understanding objective performance goals for critical limb ischemia trials. Semin Vasc Surg. 2010;23(3):129–137. doi: 10.1053/j.semvascsurg.2010.06.001
   PubMed Web of Science ®Google Scholar
• Stoner MC, Calligaro KD, Chaer RA, et al. Reporting standards of the society for vascular surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg. 2016;64(1):e1–e21. doi: 10.1016/j.jvs.2016.03.420
   PubMed Web of Science ®Google Scholar
• Fazeli B, Poredos P, Patel M, et al. Milestones in thromboangiitis obliterans: a position paper of the VAS-European independent foundation in angiology/vascular medicine. Int Angiol. 2021;40(5):395–408. doi: 10.23736/S0392-9590.21.04712-X
   PubMed Web of Science ®Google Scholar
• Rydzewski A, Urano T, Hachiya T, et al. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger’s disease. Thromb Res. 1996;84(6):445–452. doi: 10.1016/S0049-3848(96)00212-5
   PubMed Web of Science ®Google Scholar
• Cacione DG, Do Carmo Novaes F, Moreno DH. Stem cell therapy for treatment of thromboangiitis obliterans (Buerger’s disease). Cochrane Database Syst Rev. 2018;10(10):CD012794. doi: 10.1002/14651858.CD012794.pub2
   PubMedGoogle Scholar
• Salimi J, Cheraghali R, Omrani Z, et al. Surgical treatment options for Buerger’s disease (experience with 315 Cases in Iran). Med J Islam Repub Iran. 2022;36:134. doi: 10.47176/mjiri.36.134
   PubMedGoogle Scholar
• Pu H, Jiang Y, Wu Z, et al. Endovascular excimer laser-assisted balloon angioplasty for infrapopliteal arteries in thromboangiitis obliterans: a treatment for acute-phase TAO. Front Cardiovasc Med. 2022;9:831340. doi: 10.3389/fcvm.2022.831340
   PubMed Web of Science ®Google Scholar
• Yang L, Tang J, Tian Y, et al. The preliminary outcome of laser-assisted angioplasty combined with endovascular radiofrequency ablation for thromboangiitis obliterans. Adv Ther. 2021;38(12):5700–5709. doi: 10.1007/s12325-021-01945-x
   PubMed Web of Science ®Google Scholar
• Xue S, Zhang X, Peng Z, et al. Assessment of atherectomy treatment for thromboangiitis obliterans: a single center experience. Catheter Cardiovasc Interv. 2023;102(4):713–720. doi: 10.1002/ccd.30801
   PubMed Web of Science ®Google Scholar
• Emmanuel A, Selvaraj D, Sen I, et al. D-dimer levels in patients with thromboangiitis obliterans. Natl Med J India. 2019;32(3):134–136. doi: 10.4103/0970-258X.278685
   PubMed Web of Science ®Google Scholar
• Liu X, Xie H, Zheng G, et al. The plasma D-dimer trends and their value in acute lower limb ischemia patients treated by catheter directed thrombolysis. Sci Rep. 2021;11(1):10388. doi: 10.1038/s41598-021-89905-x
   PubMed Web of Science ®Google Scholar
• Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343(12):864–869. doi: 10.1056/NEJM200009213431207
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Higuchi T, Tazaki J, et al. Successful percutaneous transcatheter angioplasty of radial artery in thromboangiitis obliterans (Buerger’s disease). JACC: Cardiovasc Interv. 2017;10(22):e205–e206. doi: 10.1016/j.jcin.2017.06.066
   PubMed Web of Science ®Google Scholar
• Firat A, Igus B. Endovascular recanalization of thromboangiitis obliterans (Buerger’s disease) in twenty-eight consecutive patients and combined antegrade-retrograde intervention in eight patients. Cardiovasc Intervent Radiol. 2019;42(6):820–828. doi: 10.1007/s00270-019-02193-x
   PubMed Web of Science ®Google Scholar
• Sirignano P, Mansour W, d’Adamo A, et al. Early experience with a new concept of angioplasty nitinol-constrained balloon catheter (chocolate((r))) in severely claudicant patients. Cardiovasc Intervent Radiol. 2018;41(3):377–384. doi: 10.1007/s00270-017-1840-9
   PubMed Web of Science ®Google Scholar
• Spiliopoulos S, Karamitros A, Reppas L, et al. Novel balloon technologies to minimize dissection of peripheral angioplasty. Expert Rev Med Devices. 2019;16(7):581–588. doi: 10.1080/17434440.2019.1626715
   PubMed Web of Science ®Google Scholar